Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 285-291

  Rodenhuis, S ^a   Boerrigter, L ^a   Top, B ^a   Slebos, R J ^a   Mooi, W J ^a   van't Veer, L ^a   van Zandwijk, N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; MALE; ONCOGENE K RAS; PRIORITY JOURNAL;

EID: 0031023137     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.285     Document Type: Article

References (30)

1. Weinberg RA: Ras oncogenes and the molecular mechanisms of carcinogenesis. Blood 64:1143-1145, 1984
2. Barbacid M: Ras genes. Ann Rev Biochem 56:799-827, 1987
3. Marx J: New genes may shed light on cell growth control. Science 257:484-485, 1992
4. Rodenhuis S: Ras in human tumors. Semin Cancer Biol 3:241-247, 1992
5. Rodenhuis S, Van De Wetering ML, Mooi WJ, et al: Mutational activation of the K-ras oncogene: A possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med 317:929-935, 1987
6. Rodenhuis S, Slebos RJC, Evers SG, et al: K-ras oncogene activation in adenocarcinoma of the lung: Frequency and possible clinical significance. Cancer Res 48:5738-5741, 1988
7. Slebos RJC, Kibbelaar RE, Dalesio O, et al: Kirsten-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
8. Sugio K, Ishida T, Yokoyama T, et al: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903-2906, 1992
9. Rosell R, Li S, Skacel Z, et al: Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer. Oncogene 8:2407-2412, 1993
10. Mitsudomi T, Steinberg SM, Oie HK, et al: Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999-5002, 1991
11. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647, 1988
12. Sklar MD: Increased resistance to cis-diammine-dichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48:793-797, 1988
13. Wishart GC, Plumb JA, Spandidos DA, et al: H-ras transfection in mink lung epithelial cells may induce "atypical multidrug resistance." Eur J Cancer 27:673, 1991
14. McKenna WG, Weiss MC, Bakanauskas VJ, et al: The role of the H-ras oncogene in radiation resistance and metastasis, Int J Radiat Oncol Biophys 18:849-859, 1990
15. McKenna WG, Weiss MC, Endlich B, et al: Synergistic effect of the c-myc oncogene with H-ras on radioresistance. Cancer Res 50:97-102, 1990
16. Samid D, Miller AC, Rimoldi D, et al: Increased radiation resistance in transformed and non-transformed cells with elevated ras proto-oncogene expression. Radiat Res 126:244-250, 1991
17. Van Zandwijk N, Ten Bokkel Huinink WW, Wanders J, et al: Dose finding studies with carboplatin, ifosfamide, etoposide and mesna in non-small cell lung cancer. Semin Oncol 17:16-19, 1990 (suppl 2)
18. Slebos RJC, Boerrigter L, Evers SG, et al: A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1:136-141, 1992
19. Verlaan de Vries M, Bogaard ME, van den Elst H, et al: A dotblot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. Gene 50:313-320, 1986
20. Takeda S, Ichii S, Nakamura Y: Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat 2:112-117, 1993
21. Kahn SM, Jiang W, Culbertson TA, et al: Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 6:1079-1083, 1991
22. Slebos RJC, Hruban RN, Dalesio O, et al: K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83:1024-1027, 1991
23. Rodenhuis S: Ras oncogenes and human lung cancer, in Pass HI, Mitchell J, Johnson DH, et al: (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott, 1996, pp 73-82
24. Westra WH, Slebos RJC, Offerhaus GJA, et al: K-ras oncogene activation in lung adenocarcinomas from former smokers: Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72:432-438, 1993
25. Li ZH, Zheng J, Weiss LM: Shibata D: c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 144: 303-309, 1994
26. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462, 1992
27. Tsai CM, Chang KT, Perng RP, et al: Correlation of intrinsic chemoresistance on non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901, 1993
28. Thorgeirsson UP, Turpeenniemi/Hujanen T, Williams JE, et al: NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice. Mol Cell Biol 5:259-262, 1985
29. Muschel RJ, Williams JE, Lowy DR, et al: Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 121:1-8, 1985
30. Collard JG, Schijven JF, Roos E: Invasive and metastatic potential induced by ras-transfection into mouse BW5147 T-lymphoma cells. Cancer Res 47:754-759, 1987